cergutuzumab amunaleukin + atezolizumab

**cergutuzumab amunaleukin + atezolizumab** is a combination of two biologic cancer immunotherapies under investigation for advanced or metastatic solid tumors, particularly those expressing carcinoembryonic antigen (CEA). - **Cergutuzumab amunaleukin** is a recombinant fusion protein (immunocytokine) consisting of an engineered interleukin-2 variant (IL-2v) fused to a high-affinity monoclonal antibody targeting CEA. The IL-2v moiety abolishes binding to IL-2 receptor \u03b1 (CD25) to reduce preferential Treg activation, thus enhancing anti-tumor T cell and NK cell activity within the tumor microenvironment while sparing regulatory T cells[1][2][5][8]. - **Atezolizumab** (brand name TECENTRIQ) is a humanized IgG1 monoclonal antibody that blocks programmed death-ligand 1 (PD-L1), thereby preventing inhibition of T cell\u2013mediated antitumor responses[3][6]. The combination is being studied as a regimen to synergistically enhance anti-tumor immunity by promoting effector lymphocyte expansion and reversing tumor-mediated immunosuppression. The combination is in early clinical development for advanced CEA-expressing solid tumors, in patients who have failed or are intolerant to standard therapies[1][4][7].

Other names

cergutuzumab amunaleukin and atezolizumabCEA-IL2v and atezolizumabCEA-IL-2v and atezolizumabCEA-IL 2v and atezolizumab